Halozyme Therapeutics, Inc. vs Pharming Group N.V.: Annual Revenue Growth Compared

Biotech Revenue Growth: Halozyme vs. Pharming, 2014-2023

__timestamp	Halozyme Therapeutics, Inc.	Pharming Group N.V.
Wednesday, January 1, 2014	75334000	25762439
Thursday, January 1, 2015	135057000	11838278
Friday, January 1, 2016	146691000	16693660
Sunday, January 1, 2017	316613000	107517335
Monday, January 1, 2018	151862000	154575611
Tuesday, January 1, 2019	195992000	189333721
Wednesday, January 1, 2020	267594000	228394666
Friday, January 1, 2021	443310000	189853037
Saturday, January 1, 2022	660116000	205622000
Sunday, January 1, 2023	829253000	245316000
Monday, January 1, 2024	1015324000

In pursuit of knowledge

A Tale of Two Biotechs: Revenue Growth from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and market influence. Over the past decade, Halozyme Therapeutics, Inc. and Pharming Group N.V. have showcased contrasting trajectories in their annual revenue growth.

From 2014 to 2023, Halozyme Therapeutics, Inc. experienced a remarkable surge, with its revenue growing by over 1,000%. This impressive growth reflects the company's strategic advancements and successful product developments. In contrast, Pharming Group N.V. saw a more modest increase of approximately 850% during the same period, indicating steady progress in its market endeavors.

The year 2023 marked a significant milestone, with Halozyme's revenue reaching nearly 3.4 times that of Pharming. This comparison highlights the competitive landscape of the biotech industry, where innovation and strategic execution are paramount.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025